Myozyme approval leads to rich royalty pact

Genzyme's success in gaining approval for Myozyme, an enzyme replacement therapy for the extremely rare Pompe disease, is proving a boon for the biotech that originally developed it. Synpac, a subsidiary of a Taiwanese company, agreed to a 15-year royalty sharing deal for Myozyme that will net up to $821 million. Genzyme licensed the therapeutic in 2000 for Pompe's disease.

- here's the report on the pact from BiotechEast

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.